

28 Mar 2021 |

Quick Listen: Scrip's Five Must-Know Things

by [Ian Haydock](#)

In this week's podcast version of Five Must-Know Things, hear about a research setback in Huntington's, big R&D investment at Boehringer, a Pfizer divestment in China, Lilly's biomedicines plans, and the pandemic's impact on launches and promotion.

Join us for an audio catch-up on the major events in the biopharma industry in the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 26 March 2021, including: a setback in Huntington's; big R&D investment at Boehringer; a Pfizer divestment in China; Lilly's biomedicines plans; and the pandemic's impact on launches and promotion.

These and all other podcasts are available on the Informa Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#) and [TuneIn](#) - and also now on [Spotify Podcasts](#) - and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Roche Shelves Phase III Huntington's Candidate Tominersen](#)" - Scrip, 23 Mar, 2021.)

(Also see "[Boehringer Ingelheim Backs R&D With Big Bucks](#)" - Scrip, 24 Mar, 2021.)

(Also see "[Pfizer Throws In China Biosimilar Towel, Divests Site To WuXi](#)" - Scrip, 19 Mar, 2021.)

(Also see "[Lilly's Bio-Medicines Portfolio Grows To Offset Pressures In Key Markets](#)" - Scrip, 22 Mar, 2021.)

(Also see "[Pandemic Perspectives: COVID-19 Upended Drug Launches In Ways That Will Stick](#)" - Scrip, 24 Mar, 2021.)

[Click here to explore this interactive content online](#) 